TDP 43 News and Research

RSS

Exploring new therapeutic targets and biomarkers for neurodegenerative disorders

In this interview, Dr. Shebna Massey discusses neurodegenerative diseases such as Alzheimer's, Parkinson's, Huntington's, and more. She also discusses and explores new therapeutic targets and biomarkers for these diseases.

From Sino Biological Inc. 26 Oct 2022

TDP-43 can be useful biomarker for identifying neuropathological subtypes of frontotemporal dementia

Frontotemporal dementia (FTD) is one of the most common causes of progressive dementia in working-age people.

20 Oct 2022

Molecular probes can track the progress of protein that misbehaves in neurodegenerative diseases

A team of researchers from the IIT-Istituto Italiano di Tecnologia (Italian Institute of Technology) has designed in silico "molecular probes" able to track the progress of a protein that misbehaves in different neurodegenerative diseases, such as Amyotrophic Lateral Sclerosis (ALS) and Fronto-Temporal Dementia (FTD).

9 Sep 2022

Immuno-infrared sensor identifies Alzheimer's disease in the blood up to 17 years in advance

A sensor identifies misfolded protein biomarkers in the blood. This offers a chance to detect Alzheimer's disease before any symptoms occur. Researchers intend to bring it to market maturity.

21 Jul 2022

Research suggests a new pathway for developing Parkinson's disease

There is currently no cure for Parkinson's disease (PD), and one of the main difficulties for developing treatments is that we don't know exactly how or why the disease occurs.

4 Jul 2022

Research may pave the way for a future test to diagnose ALS

Amyotrophic lateral sclerosis (ALS) is a progressive disease of the nervous system. It affects nerve cells in the brain and spinal cord called motor neurons.

21 Jun 2022

New research provides credible estimates for prevalence of Alzheimer’s-like brain disorder

New National Institutes of Health-funded research shows that the prevalence of brain changes from Limbic-predominant Age-related TDP-43 Encephalopathy (LATE) may be roughly 40% in older adults and as high as 50% in people with Alzheimer's disease.

13 Jun 2022

Study provides the most definitive assessment of new non-Alzheimer’s dementia

Researchers from the University of Kentucky's Sanders-Brown Center on Aging say a paper recently published in Acta Neuropathologica is the most definitive assessment yet of the prevalence of a form of dementia classified in 2019 and now known as LATE.

13 Jun 2022

Antibiotic rifampicin attenuates C9orf72-linked dementia in genetically modified mice

What did Stephen Hawking and Mao Zedong have in common? They both suffered from Amyotrophic Lateral Sclerosis (ALS), a cure for which remains elusive. Scientists from Osaka Metropolitan University took an important step toward prevention of ALS and another brain disorder called Frontotemporal dementia (FTD) with their research on the effects of the antibiotic rifampicin on genetically modified mice.

23 May 2022

Little-known protein found to play a role in common neurodegenerative disorder

Scientists have known for years that amyloid fibrils -; fibrous, ropelike structures formed by closely linked protein molecules -; are present in the brains of patients with Alzheimer's and Parkinson's diseases and likely play a role in the progression of these disorders.

20 Apr 2022

University of Kentucky begins world’s first clinical trial for LATE

The motivation driving the work of Pete Nelson, M.D., Ph.D., is personal. His grandmother, Sylvia Becker, died with Alzheimer's disease, and he says his mother then grew terrified of developing the disease.

17 Mar 2022

Novel molecular pathway shared by two neurodegenerative disorders discovered

Scientists from two independent research teams have discovered how the mislocalization of a protein, known as TDP-43, alters the genetic instructions for UNC13A, providing a possible therapeutic target that could also have implications in treating amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other forms of dementia.

28 Feb 2022

Research reveals why a common genetic variant worsens outcomes for people with ALS and FTD

A pioneering new study led by UCL and National Institutes of Health (NIH) scientists has revealed, for the first time, why a common genetic variant worsens disease outcomes for people with the devastating adult-onset neurodegenerative diseases amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

24 Feb 2022

Nine new Discovery Grants awarded to fuel the development of ALS treatments

With promising new therapies for amyotrophic lateral sclerosis (ALS) on the horizon, now is the time for ongoing investment in research discovery that will continue to fuel the development of treatments.

10 Feb 2022

Scientists determine structure of the molecule associated with ALS for the first time

Scientists have determined for the first time the structure of the molecule associated with amyotrophic lateral sclerosis (ALS) and multiple other neurodegenerative diseases.

9 Dec 2021

Targeting the brain should be the focus of ALS therapy, not just spinal cord

The brain is indeed a target for treating ALS (amyotrophic lateral sclerosis), Northwestern Medicine scientists have discovered.

4 Dec 2021

Methylation of TDP-43 DNA linked to age-dependent motor cortex involvement in ALS

Amyotrophic lateral sclerosis (ALS) is an intractable neurological disease. Aging is a risk factor for the accumulation of TDP-43 (transduction responsive region DNA-binding protein of 43kDa) in the motor cortex. TDP-43 is a protein that tends to accumulate in increasing amounts, and the amount is strictly controlled by the splicing of TDP-43. Through cell experiments and analysis of human brain tissue, researchers at Brain Research Institute, Niigata University, led by Akihiro Sugai, M.D., Ph.D., have found that methylation of TDP-43 DNA is involved in the background of motor cortex involvement with aging in ALS

29 Sep 2021